US Bancorp
DYN icon

US Bancorp’s Dyne Therapeutics DYN Stock Holding History

US Bancorp’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.5K Buy
965
+565
+141% +$9.74K ﹤0.01% 3169
2025
Q4 		$7.82K Buy
400
+39
+11% +$739 ﹤0.01% 3404
2025
Q3 		$4.57K Buy
361
+19
+6% +$217 ﹤0.01% 3570
2025
Q2 		$3.26K Sell
342
-966
-74% -$10.6K ﹤0.01% 3756
2025
Q1 		$13.7K Sell
1,308
-301
-19% -$4.31K ﹤0.01% 3332
2024
Q4 		$37.9K Buy
1,609
+241
+18% +$7.13K ﹤0.01% 2887
2024
Q3 		$49.1K Buy
1,368
+1,212
+777% +$48.2K ﹤0.01% 2747
2024
Q2 		$5.5K Hold
156
– – ﹤0.01% 3482
2024
Q1 		$4.43K Buy
156
+77
+97% +$1.74K ﹤0.01% 3559
2023
Q4 		$1.05K Buy
79
+18
+30% +$176 ﹤0.01% 3793
2023
Q3 		$547 Hold
61
– – ﹤0.01% 3837
2023
Q2 		$686 Hold
61
– – ﹤0.01% 3849
2023
Q1 		$703 Hold
61
– – ﹤0.01% 3915
2022
Q4 		$707 Hold
61
– – ﹤0.01% 3964
2022
Q3 		$1K Buy
+61
New +$699 ﹤0.01% 3937
2022
Q2 		– Sell
-407
Closed -$4K – 4110
2022
Q1 		$4K Buy
+407
New +$3.46K ﹤0.01% 3663

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

US Bancorp's DYN Position: Q1 2026 in Review

US Bancorp increased its Dyne Therapeutics (DYN) stake by 141% in Q1 2026, buying an estimated $9.74K and bringing the position to 965 shares worth $17.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3169.

US Bancorp first reported a position in DYN in Q1 2022 and has held it in 16 quarters since. The position peaked at $49.1K in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • US Bancorp held 965 shares of Dyne Therapeutics worth $17.5K as of Q1 2026.
  • US Bancorp bought 565 Dyne Therapeutics shares in Q1 2026, an estimated $9.74K.
  • Dyne Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3169 holding.
  • US Bancorp first reported a position in Dyne Therapeutics in Q1 2022 and has held it in 16 quarters since.
  • US Bancorp's Dyne Therapeutics position peaked at $49.1K in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.